TW202413431A - 抗ｔａａ和ｃｄ３的多特異性抗體 - Google Patents

抗ｔａａ和ｃｄ３的多特異性抗體 Download PDF

Info

Publication number
TW202413431A
TW202413431A TW112117497A TW112117497A TW202413431A TW 202413431 A TW202413431 A TW 202413431A TW 112117497 A TW112117497 A TW 112117497A TW 112117497 A TW112117497 A TW 112117497A TW 202413431 A TW202413431 A TW 202413431A
Authority
TW
Taiwan
Prior art keywords
amino acid
region
antibody
sequence number
acid sequence
Prior art date
Application number
TW112117497A
Other languages
English (en)
Chinese (zh)
Inventor
司
八木繁典
佐竹佳樹
本田貴史
佐藤雅人
茶圓貴志
Original Assignee
日商安斯泰來製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商安斯泰來製藥股份有限公司 filed Critical 日商安斯泰來製藥股份有限公司
Publication of TW202413431A publication Critical patent/TW202413431A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112117497A 2022-05-12 2023-05-11 抗ｔａａ和ｃｄ３的多特異性抗體 TW202413431A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-078632 2022-05-12
JP2022078632 2022-05-12

Publications (1)

Publication Number Publication Date
TW202413431A true TW202413431A (zh) 2024-04-01

Family

ID=88730321

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112117497A TW202413431A (zh) 2022-05-12 2023-05-11 抗ｔａａ和ｃｄ３的多特異性抗體
TW112117454A TW202413430A (zh) 2022-05-12 2023-05-11 抗ｃｄ３７和ｃｄ３的雙特異性抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112117454A TW202413430A (zh) 2022-05-12 2023-05-11 抗ｃｄ３７和ｃｄ３的雙特異性抗體

Country Status (11)

Country Link
US (1) US20250304706A1 (enExample)
EP (1) EP4524248A1 (enExample)
JP (1) JPWO2023219121A1 (enExample)
KR (1) KR20250010005A (enExample)
CN (1) CN119173633A (enExample)
AU (1) AU2023268258A1 (enExample)
CA (1) CA3256973A1 (enExample)
CO (1) CO2024016725A2 (enExample)
MX (1) MX2024013928A (enExample)
TW (2) TW202413431A (enExample)
WO (2) WO2023219121A1 (enExample)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686953U (enExample) 1979-12-08 1981-07-11
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
ES2616316T3 (es) * 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
WO2014151438A1 (en) * 2013-03-15 2014-09-25 Emergent Product Development Seattle, Llc Multispecific anti-cd37 antibodies and related compositions and methods
TWI646108B (zh) 2013-08-01 2019-01-01 艾澤西公司 結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
PT3083689T (pt) * 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN110087682B (zh) * 2016-12-19 2023-12-15 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
CA3075693A1 (en) * 2017-09-22 2019-03-28 WuXi Biologics Ireland Limited Bispecific polypeptide complexes
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
CA3200860A1 (en) 2020-11-16 2022-05-19 Astellas Pharma Inc. Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
JP7365654B2 (ja) 2021-04-22 2023-10-20 アステラス製薬株式会社 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体

Also Published As

Publication number Publication date
MX2024013928A (es) 2024-12-06
WO2023219120A1 (ja) 2023-11-16
CA3256973A1 (en) 2025-06-17
KR20250010005A (ko) 2025-01-20
TW202413430A (zh) 2024-04-01
CO2024016725A2 (es) 2024-12-19
JPWO2023219121A1 (enExample) 2023-11-16
EP4524248A1 (en) 2025-03-19
AU2023268258A1 (en) 2024-11-28
WO2023219121A1 (ja) 2023-11-16
US20250304706A1 (en) 2025-10-02
CN119173633A (zh) 2024-12-20

Similar Documents

Publication Publication Date Title
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
EP3733715A1 (en) Triabody, preparation method and use thereof
KR20220071263A (ko) Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
US20200299412A1 (en) Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
US20230322952A1 (en) Multispecific antibodies that bind both mait and tumor cells
CA3233075A1 (en) Interleukin-2 mutant and fusion protein thereof
JP2022120846A (ja) ヒトｐｄ－ｌ１に結合する抗体
JP7078237B1 (ja) 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体
JP2023182689A (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US20250304706A1 (en) Anti-taa/anti-cd3 multispecific antibody
WO2025157223A1 (en) Multispecific antibodies and uses thereof
WO2023199927A1 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用
JP2025530110A (ja) 二重特異性ポリペプチド及びその使用
HK40090244A (zh) 结合mait和肿瘤细胞两者的多特异性抗体
EA048433B1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3